Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
OBJECTIVE
The purpose of this study was to evaluate the short-term efficacy and safety of repeated intravitreal bevacizumab for myopic choroidal neovascularization.


METHODS
We performed a prospective, nonrandomized, interventional case series study. Sixteen eyes from 16 patients with myopic choroidal neovascularization secondary to pathologic myopia had a monthly injection of intravitreal bevacizumab 1.25 mg for 3 consecutive months. Best-corrected visual acuity assessment, optical coherence tomography, fluorescein angiography and multifocal electroretinogram were performed before treatment and at 1, 2, 3, and 6 months.


RESULTS
The mean logarithm of minimum angle of resolution best-corrected visual acuity was 1.43 before treatment. At 6 months after treatment, the mean best-corrected visual acuity improved significantly (P = 0.02) to 0.7. Fluorescein angiography demonstrated absence of leakage in 14 eyes (87.5%) and persistent but decreased leakage in the remaining 2 eyes (12.5%). Optical coherence tomography showed a highly significant reduction in the foveal central thickness (P < 0.001) at all follow-up visits. The foveal and parafoveal rings showed a significant improvement in the multifocal electroretinogram responses. At the sixth month follow-up, the P1 amplitudes and implicit time P values in the foveal and parafoveal rings were <0.01 and <0.001, respectively. None of the remaining three rings showed any significant change throughout the study period.


CONCLUSIONS
In 6-month follow-up, repeated injections of intravitreal bevacizumab were effective in treating myopic choroidal neovascularization. No adverse effect was detected on retinal function evaluated by multifocal electroretinogram.
Mansoura Ophthalmic Center, Mansoura, Egypt. daliasabry73@yahoo.com
Dalia
D
Sabry
Mohammad A
MA
Gad
Kamal M
KM
Enam
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D002199:Capillary Permeability; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004596:Electroretinography / Q000187:drug effects*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications* / Q000503:physiopathology; D011446:Prospective Studies; D019233:Retreatment; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab